PhiKan 083 Inhibits MYCN Expression in Liver Cancer Cells Independent of p53 Pathways. [PDF]
Xu Y +8 more
europepmc +1 more source
MYCN-driven metabolic remodelling of the tumour microenvironment in neuroblastoma: implications for stromal biology and CAF heterogeneity. [PDF]
Shiferaw MS, Somers K, Kovacevic Z.
europepmc +1 more source
A five-gene TAM and MYCN signature predicts prognosis and identifies MTHFD2 as a therapeutic target in neuroblastoma. [PDF]
Huang Y +5 more
europepmc +1 more source
5-hydroxymethylcytosine deposition mediates Polycomb repressive complex 2 function in <i>MYCN</i>-amplified neuroblastoma. [PDF]
Chennakesavalu M +13 more
europepmc +1 more source
Integrative precision oncology in neuroblastoma: multi-omics biomarkers, molecular targets, and immunotherapeutic strategies. [PDF]
Singh A +8 more
europepmc +1 more source
Targeting the MYCN interaction network in neuroblastoma. [PDF]
Yow CX, Yeoh S, Leen E, Bayliss R.
europepmc +1 more source
The Role of Precision Medicine in Neuroblastoma: Targeted Therapies and Personalized Approaches-A Narrative Review. [PDF]
Mawa MJ, Biswas MS, Haque M, Podder MK.
europepmc +1 more source
Molecular Iodine/<i>PPARγ</i> Interaction in the Invasion and Angiogenesis of Neuroblastoma Xenografts. [PDF]
Juvera-Avalos ER +5 more
europepmc +1 more source
Expanding the molecular grading criteria in IDH-mutant astrocytoma. [PDF]
Virata MC +28 more
europepmc +1 more source
MYCN and helicases DDX17 and DDX5 have opposite effects on the production of readthrough-associated chimeric transcripts. [PDF]
Clerc V +12 more
europepmc +1 more source

